Health insurers are pushing back against one of medicine's most expensive technologies amid growing evidence it may not be better for patients than cheaper options.
Proton therapy for prostate cancer comes under attack
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.